[
  {
    "ts": "2025-12-06T05:34:19+00:00",
    "headline": "Jim Cramer on Bristol-Myers’ Recent Stock Gain: “Unbelievable”",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer commented on along with the recent macro rally. Cramer mentioned the stock during the episode, as he commented: “Then it might be a comeback to the drug stocks. Why? Well, remember, lots of people think the economy is stalled or in a tailspin. They’re […]",
    "url": "https://finance.yahoo.com/news/jim-cramer-bristol-myers-recent-053419979.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "f67275bd-cac4-3854-8742-3753b9fa6def",
      "content": {
        "id": "f67275bd-cac4-3854-8742-3753b9fa6def",
        "contentType": "STORY",
        "title": "Jim Cramer on Bristol-Myers’ Recent Stock Gain: “Unbelievable”",
        "description": "",
        "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer commented on along with the recent macro rally. Cramer mentioned the stock during the episode, as he commented: “Then it might be a comeback to the drug stocks. Why? Well, remember, lots of people think the economy is stalled or in a tailspin. They’re […]",
        "pubDate": "2025-12-06T05:34:19Z",
        "displayTime": "2025-12-06T05:34:19Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/7b1d6a1350c79cef49b9cb2889204dd6",
          "originalWidth": 1000,
          "originalHeight": 666,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/E2lv2kKRF2jXt8F.V84xVw--~B/aD02NjY7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/7b1d6a1350c79cef49b9cb2889204dd6.cf.webp",
              "width": 1000,
              "height": 666,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BN9PfJYu5RffW4DiInJR2Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/7b1d6a1350c79cef49b9cb2889204dd6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-bristol-myers-recent-053419979.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-bristol-myers-recent-053419979.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-06T12:01:00+00:00",
    "headline": "Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions",
    "summary": "BOSTON, December 06, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with sev",
    "url": "https://finance.yahoo.com/news/vertex-presents-data-casgevy-including-120100503.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "d946f10c-b814-3641-b0b6-5f0352ad3efa",
      "content": {
        "id": "d946f10c-b814-3641-b0b6-5f0352ad3efa",
        "contentType": "STORY",
        "title": "Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions",
        "description": "",
        "summary": "BOSTON, December 06, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with sev",
        "pubDate": "2025-12-06T12:01:00Z",
        "displayTime": "2025-12-06T12:01:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/fde3ffcf9460b70add028648e0b0b1a2",
          "originalWidth": 480,
          "originalHeight": 252,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0XoAXGU9JD8rqiDnRmkkFA--~B/aD0yNTI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/fde3ffcf9460b70add028648e0b0b1a2.cf.webp",
              "width": 480,
              "height": 252,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mRO427rmo07uZaVJhVcYIA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/fde3ffcf9460b70add028648e0b0b1a2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-presents-data-casgevy-including-120100503.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-presents-data-casgevy-including-120100503.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]